Skip to main content
. 2019 Mar 12;10(21):2041–2054. doi: 10.18632/oncotarget.26724

Figure 1. Association of CD164 expression in glioma with clinicopathological parameters.

Figure 1

(A) Representative images of CD164 immunostaining in normal brain and low- and high- grade gliomas. Lung cancer tissue was used as positive control. (B) CD164 gene expression analysis in a human glioma microarray dataset (GSD1962) containing 23 non-tumor samples, 76 cases of WHO grade II and III astrocytoma, and 81 cases of GBM (WHO grade IV). mRNA expression was analyzed using ANOVA. *p < 0.05, **p < 0.01, and ***p < 0.001 versus non-tumor brain tissues.